Pharmaron Beijing Co., Ltd. (03759) has officially announced a change in its corporate authorized representative role, effective August 20, 2026.

According to the company's latest filing, Mr. Lou Xiaoqiang, a board director, has stepped down from his position as the authorized representative under Rule 3.05 of the Listing Rules due to a realignment of his work responsibilities. His resignation from this specific role takes effect on the aforementioned date.

In a swift succession move, the board has approved the appointment of fellow director Mr. Li Chengzong to assume the authorized representative duties, filling the vacancy left by Mr. Lou on the same day.

It is important to note that Mr. Lou's departure from the authorized representative position does not affect his other executive roles. He will continue to serve as the company's Chief Operating Officer, President, and Executive Director, with no changes to his existing authority and responsibilities.